Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Mol Ther. 2018 Mar 7;26(3):774-783. doi: 10.1016/j.ymthe.2018.01.001. Epub 2018 Jan 8.
Chemoresistance is one of the causes of adverse effects in gastric cancer, including a poor response to cisplatin (DDP). Exosomes loaded with microRNA (miRNA), mRNA, and other non-coding RNAs could regulate drug resistance. Exo-anti-214 was extracted and verified. A Cell Counting Kit-8 (CCK-8) cell viability assay, flow cytometry, and transwell and immunofluorescence assays were performed to determine whether exo-anti-214 could sensitize cells to DDP in vitro. A combination of intravenously injected exo-anti-214 and intraperitoneal DDP was utilized in vivo. Additionally, potential targets of miR-214 were screened by mass spectrometry (MS) and confirmed via western blotting (WB). The levels of miR-214 in the human immortalized gastric epithelial cell line ges-1 and the human gastric adenocarcinoma cell lines SGC7901 and SGC7901/DDP gradually increased. Exo-anti-214 could fuse with cells and regulate potential targets, reducing cell viability, suppressing migration, and promoting apoptosis in vitro. Caudally injected exo-anti-214 was applied to reverse chemoresistance and repress tumor growth in vivo due to the downregulation of miR-214 and overexpression of possible target proteins in tumors. Exo-anti-214 could reverse the resistance to DDP in gastric cancer, which might serve as a potential alternative for the treatment of cisplatin-refractory gastric cancer in the future.
化学耐药性是胃癌不良影响的原因之一,包括对顺铂(DDP)的反应不佳。负载 microRNA(miRNA)、mRNA 和其他非编码 RNA 的外泌体可以调节药物耐药性。提取并验证了 Exo-anti-214。通过细胞计数试剂盒-8(CCK-8)细胞活力测定、流式细胞术、Transwell 和免疫荧光测定来确定 Exo-anti-214 是否可以在体外使细胞对 DDP 敏感。通过静脉注射 Exo-anti-214 和腹腔内 DDP 的组合进行体内实验。此外,通过质谱(MS)筛选 miR-214 的潜在靶标,并通过 Western blot(WB)进行验证。人永生化胃上皮细胞系 ges-1 和人胃腺癌细胞系 SGC7901 和 SGC7901/DDP 中的 miR-214 水平逐渐升高。Exo-anti-214 可以与细胞融合并调节潜在靶标,从而降低细胞活力,抑制迁移并促进体外细胞凋亡。由于肿瘤中 miR-214 的下调和可能的靶蛋白的过表达,尾静脉注射 Exo-anti-214 可以逆转体内的化学耐药性并抑制肿瘤生长。Exo-anti-214 可以逆转胃癌对 DDP 的耐药性,这可能成为未来治疗顺铂耐药性胃癌的潜在替代方法。